365
Participants
Start Date
November 12, 2019
Primary Completion Date
May 25, 2024
Study Completion Date
May 25, 2024
Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)
TDV subcutaneous injection
Placebo
Normal Saline (0.9% NaCl) subcutaneous injection
Optima Research, Rockville
AES - DRS - Optimal Research Alabama - Huntsville, Huntsville
AES - DRS - Optimal Research Illinois - Peoria, Peoria
AES - DRS - Synexus Clinical Research US, Inc. - St. Louis, St Louis
Alliance for Multispecialty Research, LLC - Newton - PPDS, Newton
AES - DRS - Synexus Clinical Research US, Inc. - Omaha, Papillion
AES - DRS - Synexus Clinical Research US, Inc. Minneapolis, Richfield
Advanced Clinical Research/Velocity Clinical Research, West Jordan
Instituto Nacional de Pediatria, Mexico City
CAIMED Investigacion en Salud S.A de C.V., Mexico City
Lead Sponsor
Takeda
INDUSTRY